Faculty of Health Sciences, Simon Fraser University, 8888 University Drive, Burnaby, BC, Canada V5A 1S6; Child and Family Research Institute, BC Children's and Women's Hospital, 950 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4.
Child and Family Research Institute, BC Children's and Women's Hospital, 950 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4.
Environ Res. 2014 Aug;133:338-47. doi: 10.1016/j.envres.2014.06.012. Epub 2014 Jul 12.
Associations between perfluoroalkyl acids (PFASs) and human thyroid hormone levels remain unclear, especially during early pregnancy when small changes in maternal thyroid hormones can affect fetal brain development.
To examine associations between maternal serum PFAS levels and maternal thyroid hormone levels in the early 2nd trimester of pregnancy.
Participants were euthyroid pregnant women (n=152) enrolled in the Chemicals, Health and Pregnancy (CHirP) study based in Vancouver, Canada. Associations between maternal serum PFASs, including perfluorohexanesulfonate (PFHxS), perfluorononanoate (PFNA), perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) and repeated measures of maternal thyroid hormones, including free thyroxine (fT4), total thyroxine (TT4) and thyroid stimulating home (TSH) were examined using mixed effects linear models. Associations were considered in all women, then separately in women with high (≥ 9 IU/mL) vs normal (<9 IU/mL) levels of thyroid peroxidase antibody (TPOAb), a marker of autoimmune hypothyroidism (Hashimoto's disease).
Median PFAS concentrations (ng/mL) in maternal sera were 1.0 (PFHxS), 0.6 (PFNA), 1.7 (PFOA) and 4.8 (PFOS). PFASs were not associated with fT4, TT4 or TSH among women with normal TPOAb. However, among the 9% of women with high TPOAb (n=14), interquartile range (IQR) increases of PFASs were associated with a 46-69% increase in maternal TSH (95% CIs ranging from 8% to 123%) (PFNA, PFOA and PFOS only), and with a 3% to 7% decrease in maternal fT4 (95% CIs ranging from -18% to 5%) (all 4 PFASs). PFNA was also associated with higher maternal TSH in the whole sample.
PFASs were positively associated with TSH, and weakly negatively associated with fT4 in the subset of pregnant women with high TPOAb, which occurs in 6-10% of pregnancies. PFASs may exacerbate the already high TSH and low fT4 levels in these women during early pregnancy, which is a critical time of thyroid hormone-mediated fetal brain development. The clinical significance of these findings is not clear. We propose a "multiple hit hypothesis" to explain these findings; this hypothesis deserves evaluation in larger, more representative study samples.
全氟烷基酸(PFAS)与人体甲状腺激素水平之间的关系仍不清楚,尤其是在妊娠早期,此时母体甲状腺激素的微小变化会影响胎儿大脑发育。
研究妊娠中期早期母体血清 PFAS 水平与母体甲状腺激素水平之间的关系。
参与者为加拿大温哥华化学、健康和妊娠(CHirP)研究中的甲状腺功能正常的孕妇(n=152)。采用混合效应线性模型,研究了母体血清 PFAS(包括全氟己烷磺酸(PFHxS)、全氟壬酸(PFNA)、全氟辛酸(PFOA)和全氟辛烷磺酸(PFOS))与重复测量的母体甲状腺激素(游离甲状腺素(fT4)、总甲状腺素(TT4)和促甲状腺激素(TSH))之间的关系。在所有女性中考虑了这些关联,然后在甲状腺过氧化物酶抗体(TPOAb)水平较高(≥9 IU/mL)与正常(<9 IU/mL)的女性中分别考虑了这些关联,TPOAb 是自身免疫性甲状腺功能减退症(桥本氏病)的标志物。
母体血清中 PFAS 浓度中位数(ng/mL)分别为 1.0(PFHxS)、0.6(PFNA)、1.7(PFOA)和 4.8(PFOS)。在 TPOAb 正常的女性中,PFAS 与 fT4、TT4 或 TSH 均无关。然而,在 9%的 TPOAb 较高的女性(n=14)中,PFAS 的四分位距(IQR)增加与 TSH 增加 46-69%(95%置信区间范围为 8%至 123%)(仅 PFNA、PFOA 和 PFOS)相关,与 fT4 降低 3%-7%(95%置信区间范围为-18%至 5%)(所有 4 种 PFAS)相关。PFNA 也与整个样本中的较高 TSH 相关。
在 TPOAb 较高的孕妇亚组中,PFAS 与 TSH 呈正相关,与 fT4 呈弱负相关,TPOAb 在 6-10%的妊娠中发生。PFAS 可能会在妊娠早期加剧这些女性已经很高的 TSH 和低 fT4 水平,这是甲状腺激素介导的胎儿大脑发育的关键时期。这些发现的临床意义尚不清楚。我们提出了一个“多重打击假说”来解释这些发现;该假说值得在更大、更具代表性的研究样本中进行评估。